|
Journal of Postgraduate Medicine
Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
ISSN: 0022-3859 EISSN: 0022-3859
Vol. 56, No. 2, 2010, pp. 163-167
|
Bioline Code: jp10044
Full paper language: English
Document type: Review Article
Document available free of charge
|
|
Journal of Postgraduate Medicine, Vol. 56, No. 2, 2010, pp. 163-167
en |
Posaconazole
Bhattacharya, M.; Rajeshwari, K. & Dhingra, B.
Abstract
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.
Keywords
Posaconazole, invasive fungal infections, candidiasis, immunocompromised
|
|
© Copyright 2010 Journal of Postgraduate Medicine. Alternative site location: http://www.jpgmonline.com
|
|